← Therapy pipeline
Investigational · Obesity development

NN9662 (Triple)

NNC0662-0419 · Novo Nordisk

A triple agonist pairing GLP-1 and GIP signaling with amylin rather than glucagon.

GLP-1GIPamylin
Other study areas
Type 2 diabetes
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 2Updated as of November 2026
SponsorNovo Nordisk
TargetsGLP-1 + GIP + amylin
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Results availability

No numerical results shown

No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagon—
AMYamylinTargeted
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 2Phase 2 obesity development listed
Milestone → next

Latest: Novo Nordisk lists NN9662 in Phase 2 for obesity.

Next: Public obesity efficacy data and trial details.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies2 records

Phase 2

NCT07639021

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Obesity program; public efficacy results were not identified in the reviewed sources.

Phase 2

NN9662 · obesity dose-finding

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Phase 2 obesity dose-finding study; active, not recruiting. Separate from dose-escalation NCT07639021.

Related conditions and outcomes

Phase 2 studies1 record

Phase 2

NN9662 · type 2 diabetes

Glycemic control in type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Separate Phase 2 study in type 2 diabetes; registry recruiting.